Unmet Need and Chronic Liver Cancer and Hepatitis to Drive Liver Diseases Therapeutic Drugs Market to USD 11.5 Billion by 2020 - iHealthcareAnalyst, Inc.

Maryland Heights, MO, August 08, 2016 --(PR.com)-- According to a new market research report published by iHealthcareAnalyst, Inc., Liver Diseases Therapeutic Drugs Market – Global Drug Classes and Therapeutic Applications Analysis and Forecast 2013-2020, the global liver diseases therapeutic drugs market is estimated to reach USD 11.5 Billion in 2020, expanding at a CAGR of 6.2% from 2016 to 2020.

Visit the Liver Diseases Therapeutic Drugs Market – Global Drug Classes and Therapeutic Applications Analysis and Forecast 2013-2020 report at http://www.ihealthcareanalyst.com/report/liver-diseases-therapeutics-market/

Liver diseases and disorders that cause the liver to function improperly or cease functioning and it is a major problem of worldwide proportions. Liver disease may have complex effects on drug clearance, biotransformation, and pharmacokinetics. Pathogenetic factors include alterations in intestinal absorption, plasma protein binding, hepatic extraction ratio, liver blood flow, portal-systemic shunting, biliary excretion, enterohepatic circulation, and renal clearance. The global liver diseases therapeutic drugs market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug classes (antiviral, chemotherapy, Corticosteroids, immunoglobulins, immunosupressants, targeted therapy drugs and vaccines), therapeutic applications (alcohol induced liver diseases, autoimmune liver disorders, hepatocellular carcinoma, NAFLD, viral or hepatitis liver disorders), and forecasts growth trends (CAGR% - 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.

The global liver diseases therapeutic drugs market is segmented as:
1. Drug Class
1.1. Antiviral Drugs
1.2. Chemotherapy Drugs
1.3. Corticosteriods
1.4. Immunoglobulins
1.5. Immunosuppressants
1.6. Targeted Therapy Drugs
1.7. Vaccines

2. Therapeutic Application
2.1. Alcohol Induced Liver Disease
2.2. Autoimmune Liver Disorder
2.3. Hepatocellular Carcinoma
2.4. Non-Alcoholic Fatty Liver Disease (NAFLD)
2.5. Viral (Hepatitis) Liver Disorder

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World

4. Company Profiles
4.1. Abbott Laboratories
4.2. Astellas Pharma Inc.
4.3. Bristol-Myers Squibb
4.4. F. Hoffmann-La Roche Ltd.
4.5. Gilead Sciences
4.6. GlaxoSmithKline plc.
4.7. Merck & Co. Inc.
4.8. Novartis AG
4.9. Pfizer Inc.
4.10. Sanofi S.A
4.11. Takeda Pharmaceutical
4.12. Valeant Pharmaceuticals
4.13. Watson Pharmaceuticals, Inc.

About Us
iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareranalyst.com
Website: http://www.ihealthcareanalyst.com